Libtayo Demonstrates Long-Term Survival Benefit in High-Risk Skin Cancer

Regeneron Pharmaceuticals announced extended data from the Phase 3 C-POST trial, showing a sustained and clinically significant overall survival benefit for adjuvant Libtayo in patients with high-risk cutaneous squamous cell carcinoma after surgery and radiation. With a median follow-up of 44 months, the treatment reduced the risk of death by 37%. These results reinforce Libtayo's role as a standard of care for this patient group.